胃灵颗粒治疗慢性萎缩性胃炎癌前病变的临床观察

[目的]观察胃灵颗粒治疗慢性萎缩性胃炎(CAG)胃癌前病变(GPL)、中医辨证属脾虚肝郁血瘀证患者的疗效。[方法]选择确诊为GPL、中医辨证属脾虚肝郁血瘀证患者112例,随机分为2组,治疗组64例予胃灵颗粒治疗,对照组48例予胃复春治疗,12周为1个疗程,均治疗2个疗程。[结果]治疗组的临床、胃镜和病理疗效均显著优于对照组(P<0.05);2组患者抗幽门螺杆菌疗效比较差异无统计学意义(P>0.05)。[结论]胃灵颗粒对GPL有良好的疗效。     

欣胃颗粒治疗胃癌前病变气阴两虚挟瘀型患者的临床观察

[目的]评价欣胃颗粒治疗胃癌前病变气阴两虚挟瘀型患者的有效性和安全性。[方法]选择确诊为胃癌前病变、中医辨证属气阴两虚挟瘀证患者83例,随机分为2组,治疗组47例给予欣胃颗粒治疗,对照组36例给予胃复春治疗,均治疗3个月,观察临床疗效、胃镜下变化、病理疗效、血清内皮素水平及安全性指标。[结果]治疗组的临床、胃镜、病理疗效以及血清内皮素水平均显著优于对照组(P0.05),且治疗前后患者安全性指标无显著性差异。[结论]欣胃颗粒对胃癌前病变有良好的疗效,且安全。     

欣胃颗粒治疗胃癌前病变气阴两虚兼瘀毒证的临床观察

[目的]观察欣胃颗粒治疗胃癌前病变气阴两虚兼瘀、毒证患者的临床疗效。[方法]入选符合纳入标准的胃癌前病变气阴两虚兼瘀、毒证的患者40例,予以欣胃颗粒治疗12周。观察患者治疗前后的临床疗效、中医证候及胃镜下病理组织学改变,并对其结果进行统计学分析。[结果]欣胃颗粒治疗胃癌前病变气阴两虚兼瘀、毒证的临床总有效率为89.18%,中医证候为91.89%,胃黏膜病变为83.78%;治疗后的中医证候总积分明显低于治疗前,差异有统计学意义(P0.05)。[结论]欣胃颗粒治疗胃癌前病变气阴两虚兼瘀、毒证患者的临床疗效显著。     

肝胃百合汤联合西药治疗幽门螺杆菌阳性消化性溃疡肝郁气滞证的临床观察

[目的]观察肝胃百合汤联合西药治疗幽门螺杆菌(Hp)阳性消化性溃疡肝郁气滞证的临床疗效。[方法]选取Hp阳性消化性溃疡肝郁气滞证患者60例,采取随机数字表法分为2组,每组各30例。2组均予根除Hp治疗,观察组加予肝胃百合汤,对照组加予胃苏颗粒。治疗时间均为4周。比较2组患者治疗前后中医症候总积分、临床疗效及Hp根除率。[结果]2组治疗后中医症候总积分均明显下降(P0.05),且观察组低于对照组(P0.05);治疗后2组总体有效率分别为90.00%和76.67%,观察组优于对照组(P0.05);治疗后2组Hp根除率分别为86.67%和73.33%,观察组优于对照组(P0.05)。[结论]肝胃百合汤联合西药治疗Hp阳性消化性溃疡肝郁气滞证的临床疗效明显。     

莪蚕健胃汤治疗慢性萎缩性胃炎伴肠化生的临床研究

[目的]观察健脾柔肝、化痰祛瘀法治疗慢性萎缩性胃炎（CAG）伴肠化生（IM）的临床疗效。[方法]将98例患者随机分为治疗组（50例）和对照组（48例）。治疗组采用健脾柔肝、化痰祛瘀法,服用莪蚕健胃汤,对照组服用胃复春,3个月为1个疗程,2组均治疗2个疗程。[结果]治疗组临床证候疗效、胃镜疗效及病理疗效均优于对照组（P〈0.05）。[结论]健脾柔肝、化痰祛瘀法对CAG伴IM患者有一定的治疗作用,对预防胃癌具有较好的临床意义。     

欣胃颗粒治疗气阴两虚挟瘀挟毒型胃癌前病变的临床观察

[目的]评价欣胃颗粒治疗气阴两虚挟瘀挟毒型胃癌前病变（GPL）的有效性。[方法]选择中医辨证属气阴两虚挟瘀挟毒型GPL患者60例,随机分为2组：欣胃颗粒治疗组（治疗组）30例;胃复春治疗组（对照组）30例;均治疗3个月,观察2组临床、胃镜、病理疗效及胃泌素（GAS）、生长抑素（ss）的变化。[结果]治疗组的临床、胃镜、病理疗效以及GAS,SS水平结果均显著优于对照组（P〈0.05）。[结论]欣胃颗粒对GPL有良好的疗效。     

芪莲舒痞汤治疗慢性萎缩性胃炎癌前病变的临床研究

[目的]探讨以络病理论为指导的芪莲舒痞汤治疗慢性萎缩性胃炎（CAG）癌前病变（PLGC）的临床疗效。[方法]将88例符合标准的CAG伴PLGC患者随机分为芪莲舒痞汤治疗（治疗）组56例及胃复春治疗（对照）组32例,详细记录2组治疗前后临床症状及胃镜、病理、幽门螺杆菌（Hp）感染的情况。[结果]治疗组总有效率89.30%,对照组总有效率68.75%;治疗组疗效优于对照组（P〈0.05）。在患者症状积分、病理积分、Hp清除率方面,治疗组效果也优于对照组（P〈0.05或〈0.01）。[结论]芪莲舒痞汤治疗CAG PLGC疗效确切,且安全性良好,值得临床推广应用。     

益胃消瘀颗粒治疗慢性萎缩性胃炎30例

[目的]观察益胃消瘀颗粒治疗慢性萎缩性胃炎(CAG)的疗效。[方法]将符合诊断标准的病例随机分成2组,每组30例。治疗组使用益胃消瘀颗粒,3 g/次,3次/d,疗程3个月;对照组用胃复春片,4片/次,3次/d。观察2组治疗前、后临床症状、体征、胃镜及病理检查结果的变化。[结果]2组治疗后症状、体征、胃镜及病理检查结果均较治疗前好转,治疗后治疗组与对照组比较差异有统计学意义(P<0.05-<0.01)。[结论]使用益胃消瘀颗粒治疗CAG有较好的疗效。     

苦参碱联合胃复春片对慢性萎缩性胃炎癌前病变患者胃酸分泌功能的影响

目的探讨苦参碱联合胃复春片对慢性萎缩性胃炎(chronic atrophic gastritis,CAG)癌前病变患者胃酸分泌功能的影响.方法入选浙江省永康医院消化内科160例CAG癌前病变患者,其中80例予胃复春片治疗为对照组,另80例予胃复春片联合苦参碱治疗为研究组.比较2组治疗前后的胃液检测、病理积分、胃镜检查等结果及临床综合疗效.结果治疗后,2组胃液pH值、游离酸、胆汁酸、胃蛋白酶值均明显改善(P0.05),研究组pH值、游离酸、胃蛋白酶值改善优于对照组(P0.05);2组萎缩、肠上皮化生、异型增生积分均明显降低(P0.05),研究组萎缩、肠上皮化生积分明显低于对照组(P0.05);研究组胃镜下能观察到的溃疡、充血水肿、糜烂、糜烂、出血斑的比例明显低于对照组(P0.05);研究组总有效率明显高于对照组(93.8%vs 86.2%,P0.05).结论苦参碱联合胃复春片治疗CAG癌前病变可有效逆转癌前病变,提高疗效,恢复胃酸分泌功能.     

欣胃颗粒治疗胃癌前病变疗效观察

[目的]观察欣胃颗粒治疗胃癌前病变(PLGC)患者的临床疗效.[方法]选择西医确诊为PLGC、中医辨证为气阴两虚挟血瘀证患者60例,随机分为2组,治疗组30例,给予欣胃颗粒,每次1袋,每日3次,共服3个月;对照组30例,给予胃复春,每次4片,每日3次,疗程同治疗组.比较2组患者治疗后的临床、胃镜、病理、幽门螺杆菌(Hp)疗效.[结果]2组在症状、胃镜、病理、Hp方面均有效,治疗组总有效率为92.86％,对照组为60.71％,治疗组明显优于对照组(P＜0.05).[结论]欣胃颗粒治疗PLGC有较好疗效.     

State of knowledge of helminth fauna of freshwater fishes of Poland

A total 89 fish and lamprey species has been recorded from Polish freshwater habitats. Twenty-seven of them (30.3%) have not been surveyed for parasitic helminthes. Some of the latter fishes are either rare or not easily accessible. Other live only in specific habitats in scattered localities. An important obstacle for studying parasite faunas of some fishes may be their status on an endangered species. Among the non-surveyed fishes, are those which have been relatively recently introduced to Poland or migrated there on their own. The present paper attempts to review all hitherto not studied helminthologically fish species, their habitats, localities and current protection status.     

高血压降压治疗目标的再认识

根据传统的高血压水平的定义,1993年WHO高血压治疗指南提出血压控制目标为<140/90mm Hg(1mm Hg=0.133kPa),但是并非所有患者都必须将血压降至同一水平,而应根据患者情况进行个体化治疗。Framingham进行的一项长达10～12年的心血管事件研究发现,第5年后,正常上限血压[收缩压(SBP     

Lack of correlation of degree of villous atrophy with severity of clinical presentation of coeliac disease

BACKGROUND AND AIM: Both the clinical presentation and the degree of mucosal damage in coeliac disease vary greatly. In view of conflicting information as to whether the mode of presentation correlates with the degree of villous atrophy, we reviewed a large cohort of patients with coeliac disease. PATIENTS AND METHODS: We correlated mode of presentation (classical, diarrhoea predominant or atypical/silent) with histology of duodenal biopsies and examined their trends over time. RESULTS: The cohort consisted of 499 adults, mean age 44.1 years, 68% females. The majority had silent coeliac disease (56%) and total villous atrophy (65%). There was no correlation of mode of presentation with the degree of villous atrophy (p=0.25). Sixty-eight percent of females and 58% of males had a severe villous atrophy (p=0.052). There was a significant trend over time for a greater proportion of patients presenting as atypical/silent coeliac disease and having partial villous atrophy, though the majority still had total villous atrophy. CONCLUSIONS: Among our patients the degree of villous atrophy in duodenal biopsies did not correlate with the mode of presentation, indicating that factors other than the degree of villous atrophy must account for diarrhoea in coeliac disease.